The ETF is composed of pharmaceuticals (50%), health care providers (19%), medical equipment (16%), biotech (11%), life sciences (4%). The top 4 stocks are all drug companies ($JNJ, $PFE, $MRK, $ABT) that have been doing very well in both a risk-on and risk-off market environment.
The eventual ruling on whether Obamacare is constitutional will likely have some impact on the ETF, but any decision will have its pros and cons on the sector. What I like about $XLV is the exposure to pharmaceuticals, which are poised to continue moving higher, as well as the 2% dividend yield. Throw in the bullish chart and $XLV looks like a winner.
No comments:
Post a Comment